AGM-217

AGM-217 is a preclinical peptide drug candidate developed by Anygen and HLB Pep for the treatment of type 2 diabetes and obesity. It is designed as a triple receptor agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R), the gastric inhibitory polypeptide receptor (GIPR), and the glucagon receptor (GCGR). By integrating these three pathways, AGM-217 aims to provide superior glycemic control and weight reduction compared to mono- or dual-agonists. The GLP-1 and GIP components enhance insulin secretion and suppress appetite, while the glucagon component increases energy expenditure and lipid metabolism, potentially leading to more significant weight loss and metabolic improvement.